Published in Anal Bioanal Chem on March 15, 2013
Fatty acid-binding proteins (FABPs) are intracellular carriers for Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD). J Biol Chem (2015) 0.89
Safety and pharmacokinetics of oral cannabidiol when administered concomitantly with intravenous fentanyl in humans. J Addict Med (2015) 0.79
A urinary test procedure for identification of cannabidiol in patients undergoing medical therapy with marijuana. J Pain Res (2016) 0.75
High-potency cannabis and the risk of psychosis. Br J Psychiatry (2009) 2.41
Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb. Trends Pharmacol Sci (2009) 2.32
Pharmacokinetics and metabolism of the plant cannabinoids, delta9-tetrahydrocannabinol, cannabidiol and cannabinol. Handb Exp Pharmacol (2005) 1.63
Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action. Rev Bras Psiquiatr (2008) 1.61
Effect of cannabis and certain of its constituents on pentobarbitone sleeping time and phenazone metabolism. Br J Pharmacol (1972) 1.56
Action of cannabidiol on the anxiety and other effects produced by delta 9-THC in normal subjects. Psychopharmacology (Berl) (1982) 1.56
Effects of cannabidiol on schizophrenia-like symptoms in people who use cannabis. Br J Psychiatry (2008) 1.49
Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients. Neuropsychopharmacology (2011) 1.41
Cannabinoids in humans. I. Analysis of delta 9-tetrahydrocannabinol and six metabolites in plasma and urine using GC-MS. J Anal Toxicol (1995) 1.28
Physiochemical properties, solubility, and protein binding of delta9-tetrahydrocannabinol. J Pharm Sci (1974) 1.26
Cannabidiol interferes with the effects of delta 9 - tetrahydrocannabinol in man. Eur J Pharmacol (1974) 1.25
Different effects of nabilone and cannabidiol on binocular depth inversion in Man. Pharmacol Biochem Behav (2000) 1.13
Plasma cannabinoid pharmacokinetics following controlled oral delta9-tetrahydrocannabinol and oromucosal cannabis extract administration. Clin Chem (2010) 1.11
Simultaneous GC-EI-MS determination of Delta9-tetrahydrocannabinol, 11-hydroxy-Delta9-tetrahydrocannabinol, and 11-nor-9-carboxy-Delta9-tetrahydrocannabinol in human urine following tandem enzyme-alkaline hydrolysis. J Anal Toxicol (2007) 1.11
Characterization of the lipophilicity of natural and synthetic analogs of delta 9-tetrahydrocannabinol and its relationship to pharmacological potency. J Pharmacol Exp Ther (1990) 1.10
Cannabinoids in humans. II. The influence of three methods of hydrolysis on the concentration of THC and two metabolites in urine. J Anal Toxicol (1995) 1.09
Cannabis with high cannabidiol content is associated with fewer psychotic experiences. Schizophr Res (2011) 1.09
Safety and side effects of cannabidiol, a Cannabis sativa constituent. Curr Drug Saf (2011) 1.03
The stability of cannabis and its preparations on storage. J Pharm Pharmacol (1976) 1.01
Development of a LC/MS/MS method for the analysis of cannabinoids in human EDTA-plasma and urine after small doses of Cannabis sativa extracts. J Chromatogr B Analyt Technol Biomed Life Sci (2007) 1.00
Simultaneous quantification of free and glucuronidated cannabinoids in human urine by liquid chromatography tandem mass spectrometry. Clin Chim Acta (2012) 0.97
Validation of a two-dimensional gas chromatography mass spectrometry method for the simultaneous quantification of cannabidiol, Delta(9)-tetrahydrocannabinol (THC), 11-hydroxy-THC, and 11-nor-9-carboxy-THC in plasma. Anal Bioanal Chem (2010) 0.97
Subjective and physiological effects after controlled Sativex and oral THC administration. Clin Pharmacol Ther (2011) 0.97
Characterization of human hepatic and extrahepatic UDP-glucuronosyltransferase enzymes involved in the metabolism of classic cannabinoids. Drug Metab Dispos (2009) 0.95
Stability of delta 9-tetrahydrocannabinol (THC), 11-hydroxy-THC, and 11-nor-9-carboxy-THC in blood and plasma. J Anal Toxicol (1985) 0.91
Effect of hydrolysis on identifying prenatal cannabis exposure. Anal Bioanal Chem (2010) 0.90
Interaction between cannabidiol (CBD) and ∆(9)-tetrahydrocannabinol (THC): influence of administration interval and dose ratio between the cannabinoids. Psychopharmacology (Berl) (2011) 0.90
Detection and quantitation of urinary 11-nor-delta-9-tetrahydrocannabinol-9-carboxylic acid, a metabolite of tetrahydrocannabinol, by capillary gas chromatography and electron impact mass fragmentography. J Anal Toxicol (1987) 0.87
On-line solid-phase extraction combined with liquid chromatography-tandem mass spectrometry for high throughput analysis of 11-nor-Delta9-tetrahydrocannabinol-9-carboxylic acid in urine. J Chromatogr B Analyt Technol Biomed Life Sci (2009) 0.86
Cannabidiol: an overview of some chemical and pharmacological aspects. Part I: chemical aspects. Chem Phys Lipids (2002) 0.86
Identification of cytochrome P450 enzymes responsible for metabolism of cannabidiol by human liver microsomes. Life Sci (2011) 0.86
Metabolites of cannabidiol identified in human urine. Xenobiotica (1990) 0.82
Comparative metabolism of cannabidiol in dog, rat and man. Pharmacol Biochem Behav (1991) 0.82
Rapid and robust confirmation and quantification of 11-nor-Δ9-tetrahydrocannabinol-9-carboxylic acid (THC-COOH) in urine by column switching LC-MS-MS analysis. J Mass Spectrom (2012) 0.78
Stability, transfer and absorption of cannabinoid constituents of cannabis (hashish) during smoking. Acta Pharm Suec (1971) 0.78
Urinary metabolites of cannabidiol in dog, rat and man and their identification by gas chromatography-mass spectrometry. J Chromatogr (1991) 0.77
Automated solid-phase extraction-liquid chromatography-tandem mass spectrometry analysis of 11-nor-Delta9-tetrahydrocannabinol-9-carboxylic acid in human urine specimens: application to a high-throughput urine analysis laboratory. J Anal Toxicol (2009) 0.77
Identification of the glucuronides of cannabidiol and hydroxycannabidiols in mouse liver. Biochem Pharmacol (1976) 0.77
Essential role of the histone methyltransferase G9a in cocaine-induced plasticity. Science (2010) 3.97
Primary outcome indices in illicit drug dependence treatment research: systematic approach to selection and measurement of drug use end-points in clinical trials. Addiction (2011) 3.42
Dnmt3a regulates emotional behavior and spine plasticity in the nucleus accumbens. Nat Neurosci (2010) 3.41
Early-onset cannabis use and cognitive deficits: what is the nature of the association? Drug Alcohol Depend (2003) 2.68
Buprenorphine versus methadone in the treatment of pregnant opioid-dependent patients: effects on the neonatal abstinence syndrome. Drug Alcohol Depend (2005) 2.26
Cannabis effects on driving skills. Clin Chem (2012) 2.04
Cannabis withdrawal among non-treatment-seeking adult cannabis users. Am J Addict (2006) 1.94
Oral fluid testing for drugs of abuse. Clin Chem (2009) 1.89
Guidelines for research on drugged driving. Addiction (2008) 1.87
Methadone maintenance and breastfeeding in the neonatal period. Pediatrics (2008) 1.86
Cannabinoids in exhaled breath following controlled administration of smoked cannabis. Clin Chem (2013) 1.67
Validated gas chromatographic-negative ion chemical ionization mass spectrometric method for delta(9)-tetrahydrocannabinol in sweat patches. Clin Chem (2004) 1.66
Methamphetamine and amphetamine pharmacokinetics in oral fluid and plasma after controlled oral methamphetamine administration to human volunteers. Clin Chem (2003) 1.66
Acute nicotine differentially impacts anticipatory valence- and magnitude-related striatal activity. Biol Psychiatry (2012) 1.62
Nicotine enhances visuospatial attention by deactivating areas of the resting brain default network. J Neurosci (2007) 1.61
On-site test for cannabinoids in oral fluid. Clin Chem (2012) 1.57
Dysregulated postsynaptic density and endocytic zone in the amygdala of human heroin and cocaine abusers. Biol Psychiatry (2010) 1.56
Simultaneous quantification of cannabinoids and metabolites in oral fluid by two-dimensional gas chromatography mass spectrometry. J Chromatogr A (2010) 1.53
Adolescent cannabis exposure alters opiate intake and opioid limbic neuronal populations in adult rats. Neuropsychopharmacology (2006) 1.52
Estrogen receptor gene expression in relation to neuropsychiatric disorders. Ann N Y Acad Sci (2003) 1.51
Urinary cannabinoid detection times after controlled oral administration of delta9-tetrahydrocannabinol to humans. Clin Chem (2003) 1.48
Endocannabinoid signaling controls pyramidal cell specification and long-range axon patterning. Proc Natl Acad Sci U S A (2008) 1.47
ΔFosB induction in striatal medium spiny neuron subtypes in response to chronic pharmacological, emotional, and optogenetic stimuli. J Neurosci (2013) 1.41
Extended urinary Delta9-tetrahydrocannabinol excretion in chronic cannabis users precludes use as a biomarker of new drug exposure. Drug Alcohol Depend (2009) 1.40
[Interchangeability among therapeutics equivalents of lamotrigine in the treatment of refractory epilepsy patients: risks and benefits]. Rev Neurol (2010) 1.39
Mu opioid receptor A118G polymorphism in association with striatal opioid neuropeptide gene expression in heroin abusers. Proc Natl Acad Sci U S A (2006) 1.37
Endocannabinoids regulate interneuron migration and morphogenesis by transactivating the TrkB receptor. Proc Natl Acad Sci U S A (2005) 1.33
Matrix effect in bio-analysis of illicit drugs with LC-MS/MS: influence of ionization type, sample preparation, and biofluid. J Am Soc Mass Spectrom (2003) 1.31
Plasma pharmacokinetics of 3,4-methylenedioxymethamphetamine after controlled oral administration to young adults. Ther Drug Monit (2008) 1.29
Oral fluid cannabinoids in chronic, daily Cannabis smokers during sustained, monitored abstinence. Clin Chem (2011) 1.29
Impact of prolonged cannabinoid excretion in chronic daily cannabis smokers' blood on per se drugged driving laws. Clin Chem (2013) 1.29
Delta9-tetrahydrocannabinol (THC), 11-hydroxy-THC, and 11-nor-9-carboxy-THC plasma pharmacokinetics during and after continuous high-dose oral THC. Clin Chem (2009) 1.28
Just say "I don't": lack of concordance between teen report and biological measures of drug use. Pediatrics (2010) 1.26
Neonatal abstinence syndrome in methadone-exposed infants is altered by level of prenatal tobacco exposure. Drug Alcohol Depend (2004) 1.26
Cognitive measures in long-term cannabis users. J Clin Pharmacol (2002) 1.23
Duration of detectable methamphetamine and amphetamine excretion in urine after controlled oral administration of methamphetamine to humans. Clin Chem (2002) 1.23
Prenatal methamphetamine exposure and neonatal neurobehavioral outcome in the USA and New Zealand. Neurotoxicol Teratol (2010) 1.22
Intrauterine growth of infants exposed to prenatal methamphetamine: results from the infant development, environment, and lifestyle study. J Pediatr (2010) 1.21
Quitting among non-treatment-seeking marijuana users: reasons and changes in other substance use. Am J Addict (2006) 1.21
Role for mTOR signaling and neuronal activity in morphine-induced adaptations in ventral tegmental area dopamine neurons. Neuron (2011) 1.21
Do Delta9-tetrahydrocannabinol concentrations indicate recent use in chronic cannabis users? Addiction (2009) 1.21
Neurokinin 1 receptor and relative abundance of the short and long isoforms in the human brain. Eur J Neurosci (2003) 1.20
Prenatal and postnatal cocaine exposure predict teen cocaine use. Neurotoxicol Teratol (2010) 1.19
Disposition of cannabinoids in oral fluid after controlled around-the-clock oral THC administration. Clin Chem (2010) 1.19
Neuroadaptations in human chronic alcoholics: dysregulation of the NF-kappaB system. PLoS One (2007) 1.19
Identification of recent cannabis use: whole-blood and plasma free and glucuronidated cannabinoid pharmacokinetics following controlled smoked cannabis administration. Clin Chem (2011) 1.18
Urinary pharmacokinetics of methamphetamine and its metabolite, amphetamine following controlled oral administration to humans. Ther Drug Monit (2004) 1.16
Identifying new cannabis use with urine creatinine-normalized THCCOOH concentrations and time intervals between specimen collections. J Anal Toxicol (2009) 1.16
Oral fluid as a diagnostic tool. Clin Chem Lab Med (2004) 1.15
Phase I and II cannabinoid disposition in blood and plasma of occasional and frequent smokers following controlled smoked cannabis. Clin Chem (2014) 1.15
Differences in DNA methylation between human neuronal and glial cells are concentrated in enhancers and non-CpG sites. Nucleic Acids Res (2013) 1.15
Estimating time of last oral ingestion of cannabis from plasma THC and THCCOOH concentrations. Ther Drug Monit (2006) 1.15
Effects of dose and route of administration on pharmacokinetics of (+ or -)-3,4-methylenedioxymethamphetamine in the rat. Drug Metab Dispos (2009) 1.15
The dose effects of short-term dronabinol (oral THC) maintenance in daily cannabis users. Drug Alcohol Depend (2012) 1.14
Prenatal cannabis exposure increases heroin seeking with allostatic changes in limbic enkephalin systems in adulthood. Biol Psychiatry (2006) 1.12
Concentrations of methadone in breast milk and plasma in the immediate perinatal period. J Hum Lact (2007) 1.12
Miswiring the brain: Δ9-tetrahydrocannabinol disrupts cortical development by inducing an SCG10/stathmin-2 degradation pathway. EMBO J (2014) 1.11
Urine testing for cocaine abuse: metabolic and excretion patterns following different routes of administration and methods for detection of false-negative results. J Anal Toxicol (2003) 1.11
Plasma cannabinoid pharmacokinetics following controlled oral delta9-tetrahydrocannabinol and oromucosal cannabis extract administration. Clin Chem (2010) 1.11
Simultaneous GC-EI-MS determination of Delta9-tetrahydrocannabinol, 11-hydroxy-Delta9-tetrahydrocannabinol, and 11-nor-9-carboxy-Delta9-tetrahydrocannabinol in human urine following tandem enzyme-alkaline hydrolysis. J Anal Toxicol (2007) 1.11
Urinary elimination of 11-nor-9-carboxy-delta9-tetrahydrocannnabinol in cannabis users during continuously monitored abstinence. J Anal Toxicol (2008) 1.10
Identification of prenatal amphetamines exposure by maternal interview and meconium toxicology in the Infant Development, Environment and Lifestyle (IDEAL) study. Ther Drug Monit (2009) 1.10
Cannabis Use during Adolescent Development: Susceptibility to Psychiatric Illness. Front Psychiatry (2013) 1.09
Cannabinoid disposition in oral fluid after controlled smoked cannabis. Clin Chem (2012) 1.09
Implications of plasma Delta9-tetrahydrocannabinol, 11-hydroxy-THC, and 11-nor-9-carboxy-THC concentrations in chronic cannabis smokers. J Anal Toxicol (2009) 1.09
Cannabinoid concentrations in hair from documented cannabis users. Forensic Sci Int (2006) 1.08
Effects of the cannabinoid-1 receptor antagonist rimonabant on psychiatric symptoms in overweight people with schizophrenia: a randomized, double-blind, pilot study. J Clin Psychopharmacol (2011) 1.08
Delta(9)-tetrahydrocannabinol, 11-hydroxy-delta(9)-tetrahydrocannabinol and 11-nor-9-carboxy-delta(9)-tetrahydrocannabinol in human plasma after controlled oral administration of cannabinoids. Ther Drug Monit (2006) 1.07
A mechanism for the inhibition of neural progenitor cell proliferation by cocaine. PLoS Med (2008) 1.07
Maternal cannabis use alters ventral striatal dopamine D2 gene regulation in the offspring. Biol Psychiatry (2011) 1.07
Isolation and characterization of new exon 11-associated N-terminal splice variants of the human mu opioid receptor gene. J Neurochem (2008) 1.07
Whole-brain circuit dissection in free-moving animals reveals cell-specific mesocorticolimbic networks. J Clin Invest (2013) 1.07
Anxiolytic-like effect of oxytocin in the simulated public speaking test. J Psychopharmacol (2011) 1.07
Neurobiological consequences of maternal cannabis on human fetal development and its neuropsychiatric outcome. Eur Arch Psychiatry Clin Neurosci (2009) 1.06
Intra- and intersubject whole blood/plasma cannabinoid ratios determined by 2-dimensional, electron impact GC-MS with cryofocusing. Clin Chem (2009) 1.05
Cannabidiol, a nonpsychotropic component of cannabis, inhibits cue-induced heroin seeking and normalizes discrete mesolimbic neuronal disturbances. J Neurosci (2009) 1.05
A liquid chromatography tandem mass spectrometry method for the simultaneous quantification of 20 drugs of abuse and metabolites in human meconium. Anal Bioanal Chem (2009) 1.05
Metabolic effects of chronic cannabis smoking. Diabetes Care (2013) 1.04
A validated method for the determination of nicotine, cotinine, trans-3'-hydroxycotinine, and norcotinine in human plasma using solid-phase extraction and liquid chromatography-atmospheric pressure chemical ionization-mass spectrometry. J Mass Spectrom (2006) 1.04
Quantification of nicotine, cotinine, trans-3'-hydroxycotinine, nornicotine and norcotinine in human meconium by liquid chromatography/tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci (2008) 1.03
Cannabinoid disposition in oral fluid after controlled cannabis smoking in frequent and occasional smokers. Drug Test Anal (2014) 1.03
Opioid neuropeptide genotypes in relation to heroin abuse: dopamine tone contributes to reversed mesolimbic proenkephalin expression. Proc Natl Acad Sci U S A (2008) 1.03
Performance effects of nicotine during selective attention, divided attention, and simple stimulus detection: an fMRI study. Cereb Cortex (2008) 1.03
Direct quantification of cannabinoids and cannabinoid glucuronides in whole blood by liquid chromatography-tandem mass spectrometry. Anal Bioanal Chem (2011) 1.03
Prenatal methamphetamine exposure and childhood behavior problems at 3 and 5 years of age. Pediatrics (2012) 1.03
A test of the cognitive self-medication hypothesis of tobacco smoking in schizophrenia. Biol Psychiatry (2013) 1.03
Effects of naltrexone on the subjective response to amphetamine in healthy volunteers. J Clin Psychopharmacol (2004) 1.03
First metabolic profile of XLR-11, a novel synthetic cannabinoid, obtained by using human hepatocytes and high-resolution mass spectrometry. Clin Chem (2013) 1.01
Physiological and subjective responses to controlled oral 3,4-methylenedioxymethamphetamine administration. J Clin Psychopharmacol (2008) 1.01
Qualitative confirmation of 9 synthetic cannabinoids and 20 metabolites in human urine using LC-MS/MS and library search. Anal Chem (2013) 1.01
The cannabinoid CB1 receptor antagonist rimonabant attenuates the hypotensive effect of smoked marijuana in male smokers. Am Heart J (2006) 1.01
Nicotine and metabolites in meconium as evidence of maternal cigarette smoking during pregnancy and predictors of neonatal growth deficits. Nicotine Tob Res (2010) 1.01
Disposition of cocaine and its metabolites in human sweat after controlled cocaine administration. Clin Chem (2005) 1.01
Major and minor metabolites of cocaine in human plasma following controlled subcutaneous cocaine administration. J Anal Toxicol (2006) 1.01
Plasma cannabinoid concentrations during dronabinol pharmacotherapy for cannabis dependence. Ther Drug Monit (2014) 1.00
Interpretation of oral fluid tests for drugs of abuse. Ann N Y Acad Sci (2007) 1.00
Strategies for quitting among non-treatment-seeking marijuana smokers. Am J Addict (2005) 1.00